Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead multiple sclerosis drug candidate, Lucid-MS, toward a randomized, double-blind, placebo-controlled Phase 2 clinical trial following clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). The company announced the development in a recent press release, highlighting the potential of Lucid-MS as a first-in-class treatment for MS.
Lucid-MS is a patented, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2). Unlike existing MS therapies that primarily suppress the immune system, Lucid-MS is designed to target demyelination directly—the underlying mechanism of multiple sclerosis. In preclinical models, the compound has been shown to prevent and reverse myelin degradation. This mechanism of action could represent a significant shift in how MS is treated, addressing the root cause of the disease rather than just managing symptoms or modulating immune response.
The FDA’s clearance of the IND application allows Quantum BioPharma to proceed with human testing, a critical step in the drug development process. The planned Phase 2 trial will evaluate the safety and efficacy of Lucid-MS in patients with MS. If successful, the drug could offer a new therapeutic option for a condition that affects millions worldwide and for which there is currently no cure.
In addition to the clinical milestone, Quantum BioPharma is collaborating with Massachusetts General Hospital and Harvard Medical School on research involving the [¹⁸F]3F4AP PET imaging tracer. This tracer is being evaluated as a method to visualize and measure demyelination, which could enhance the ability to diagnose and monitor MS progression and treatment response. Such imaging tools are essential for developing therapies that target remyelination and neuroprotection.
The press release also notes that Quantum BioPharma is among several companies advancing therapies in areas of unmet medical need. For example, Novartis AG (NYSE: NVS) recently received FDA approval for Pluvicto® in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA™ accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a Phase 2 trial of BRIUMVI® in adults with treatment-resistant schizophrenia, and Bristol-Myers Squibb Company (NYSE: BMY) reported positive Phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on the research and development of Lucid-MS. Quantum also invented UNBUZZD™ and spun out its over-the-counter version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026. The agreement includes royalty payments of 7% of sales until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
For more information, the full press release is available at https://ibn.fm/lCey9. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
